Immatics (IMTX) News Today → Biden replacement revealed? (From Paradigm Press) (Ad) Free IMTX Stock Alerts $11.67 -0.03 (-0.26%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26 at 2:44 AM | americanbankingnews.comImmatics (NASDAQ:IMTX) Sees Unusually-High Trading VolumeMay 21, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn SituationMay 20, 2024 | americanbankingnews.comImmatics (NASDAQ:IMTX) Price Target Raised to $16.00May 18, 2024 | americanbankingnews.comImmatics Expected to Earn FY2024 Earnings of ($0.85) Per Share (NASDAQ:IMTX)May 17, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Expected to Earn FY2024 Earnings of ($0.85) Per ShareImmatics (NASDAQ:IMTX - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for Immatics in a research report issued to clients and investors on Wednesday, May 15th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company wilMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising OutlookMay 16, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Given New $16.00 Price Target at MizuhoMizuho boosted their target price on shares of Immatics from $14.00 to $16.00 and gave the company a "buy" rating in a research report on Thursday.May 16, 2024 | msn.comStock Market News for May 15, 2024May 16, 2024 | marketbeat.comEquities Analysts Offer Predictions for Immatics' Q2 2024 Earnings (NASDAQ:IMTX)Immatics (NASDAQ:IMTX - Free Report) - Research analysts at Leerink Partnrs raised their Q2 2024 earnings estimates for shares of Immatics in a note issued to investors on Tuesday, May 14th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.34) per share for the quarMay 14, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Shares Gap Up to $11.00Immatics (NASDAQ:IMTX) Shares Gap Up to $11.00May 14, 2024 | globenewswire.comImmatics Announces First Quarter 2024 Financial Results and Business UpdateApril 1, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Stock Price Up 5.4%Immatics (NASDAQ:IMTX) Trading Up 5.4%March 29, 2024 | markets.businessinsider.comMaintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising PartnershipsMarch 28, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Stock Price Down 3.7%Immatics (NASDAQ:IMTX) Trading Down 3.7%March 21, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Shares Gap Down to $12.05Immatics (NASDAQ:IMTX) Shares Gap Down to $12.05March 21, 2024 | investorplace.comIMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comImmatics Announces Full Year 2023 Financial Results and Corporate UpdateMarch 19, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Sees Strong Trading VolumeImmatics (NASDAQ:IMTX) Sees Unusually-High Trading VolumeMarch 19, 2024 | marketbeat.comWellington Management Group LLP Cuts Holdings in Immatics (NASDAQ:IMTX)Wellington Management Group LLP trimmed its holdings in shares of Immatics (NASDAQ:IMTX - Free Report) by 2.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,605,157 shares of the company's stMarch 18, 2024 | marketbeat.comImmatics (IMTX) to Release Quarterly Earnings on TuesdayImmatics (NASDAQ:IMTX) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.March 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big gunsMarch 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Invests $3.78 Million in Immatics (NASDAQ:IMTX)Adage Capital Partners GP L.L.C. acquired a new stake in shares of Immatics (NASDAQ:IMTX - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 326,500 shares of the company's stock, valued at approximately $3,781,000. Adage CapMarch 10, 2024 | seekingalpha.comCantor sees strong year ahead for oncology M&AMarch 10, 2024 | msn.comCantor Fitzgerald sees strong year ahead for oncology M&AMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic PartnershipsMarch 1, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Sets New 12-Month High at $13.16Immatics (NASDAQ:IMTX) Reaches New 52-Week High at $13.16March 1, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Stock Holdings Lowered by 683 Capital Management LLC683 Capital Management LLC lowered its stake in shares of Immatics (NASDAQ:IMTX - Free Report) by 20.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,080,000 shares of the company's stock after selling 270,000 shares duFebruary 28, 2024 | seekingalpha.comEditas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must WatchFebruary 6, 2024 | uk.yahoo.comBolton TV star to 'go back to Fernandos one last time' as he spreads the loveFebruary 3, 2024 | finance.yahoo.comImmatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last yearFebruary 3, 2024 | seekingalpha.comImmatics: Pioneering TCR Therapies In The Fight Against CancerJanuary 20, 2024 | marketbeat.comTD Asset Management Inc Buys 100,200 Shares of Immatics (NASDAQ:IMTX)TD Asset Management Inc raised its stake in shares of Immatics (NASDAQ:IMTX - Free Report) by 102.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 197,718 shares of the company's stock after purchasing an additional 100,200 shares during theJanuary 17, 2024 | msn.comImmatics commences public offering of sharesJanuary 17, 2024 | finance.yahoo.comImmatics Announces Pricing of $175 Million Public OfferingJanuary 17, 2024 | finance.yahoo.comImmatics Announces Proposed Public OfferingJanuary 15, 2024 | marketbeat.comShort Interest in Immatics (NASDAQ:IMTX) Expands By 36.5%Immatics (NASDAQ:IMTX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 7,780,000 shares, an increase of 36.5% from the December 15th total of 5,700,000 shares. Based on an average trading volume of 500,000 shares, the short-interest ratio is presently 15.6 days. Approximately 15.3% of the company's shares are short sold.November 20, 2023 | markets.businessinsider.comPositive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh’s RecommendationNovember 16, 2023 | markets.businessinsider.comImmatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming CatalystsNovember 14, 2023 | markets.businessinsider.comImmatics Announces Third Quarter 2023 Financial Results and Business UpdateNovember 8, 2023 | finanznachrichten.deImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNovember 6, 2023 | finance.yahoo.comImmatics (IMTX) Moves 23.2% Higher: Will This Strength Last?November 3, 2023 | nasdaq.comCantor Fitzgerald Initiates Coverage of Immatics N.V (IMTX) with Overweight RecommendationOctober 24, 2023 | finance.yahoo.comImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyOctober 12, 2023 | msn.comDown -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)October 9, 2023 | seekingalpha.comAnalyzing Immatics' Multi-Faceted Investment CaseSeptember 21, 2023 | finance.yahoo.comIMTX Oct 2023 10.000 putSeptember 21, 2023 | marketbeat.comQ3 2023 EPS Estimates for Immatics Increased by Leerink Partnrs (NASDAQ:IMTX)Immatics (NASDAQ:IMTX - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2023 earnings per share (EPS) estimates for Immatics in a research note issued on Monday, September 18th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.35)September 11, 2023 | marketwatch.comImmatics shares rise on Moderna cancer collaborationSeptember 11, 2023 | bizjournals.comModerna enters cancer collaboration with Immatics worth $1.8BSeptember 7, 2023 | marketbeat.comImmatics (NASDAQ:IMTX) Shares Purchased by Wellington Management Group LLPWellington Management Group LLP boosted its stake in Immatics (NASDAQ:IMTX - Free Report) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,037,677 shares of the company's stock after p Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13. See his shocking evidence in this new report IMTX Media Mentions By Week IMTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMTX News Sentiment▼0.790.87▲Average Medical News Sentiment IMTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMTX Articles This Week▼31▲IMTX Articles Average Week Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mesoblast News Today ProKidney News Today Humacyte News Today Prime Medicine News Today Scholar Rock News Today Cullinan Therapeutics News Today Relay Therapeutics News Today CARGO Therapeutics News Today Autolus Therapeutics News Today REGENXBIO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMTX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.